From the FDA Press Release on September 23rd: “The U.S. Food and Drug Administration announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia.”
Now, why doesn’t the FDA suggest something BETTER than medications to control their blood sugars? And why does Avandia work in such a risky way? To find out more, see these stories from our archives, from Ron Rosedale and from Eric Westman and Mary Vernon.
And for more detail about the FDA decision, and commentary about it, here’s a summary from David Mendosa.
